Wellington Management Group LLP Raises Position in DaVita Inc. (NYSE:DVA)

Wellington Management Group LLP raised its stake in shares of DaVita Inc. (NYSE:DVA) by 9.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,711 shares of the company’s stock after purchasing an additional 227 shares during the period. Wellington Management Group LLP’s holdings in DaVita were worth $405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DVA. Copia Wealth Management purchased a new stake in DaVita during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of DaVita in the fourth quarter worth approximately $41,000. Coppell Advisory Solutions LLC raised its holdings in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock worth $45,000 after buying an additional 100 shares during the period. Canada Post Corp Registered Pension Plan purchased a new stake in shares of DaVita in the fourth quarter worth approximately $55,000. Finally, Venturi Wealth Management LLC raised its holdings in shares of DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after buying an additional 152 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Trading Up 0.1%

DVA opened at $137.95 on Friday. The stock’s fifty day moving average is $142.56 and its two-hundred day moving average is $152.07. The company has a market capitalization of $10.41 billion, a P/E ratio of 12.84, a PEG ratio of 1.07 and a beta of 1.11. DaVita Inc. has a 52 week low of $131.76 and a 52 week high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. The business had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.26 EPS. Analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Barclays increased their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Finally, Truist Financial reduced their price objective on DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a report on Monday, May 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.